In September 2025, Imugene reported that 13 of 16 participants reached an ORR of 81%.

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

A simple blood test analysed by artificial intelligence could revolutionise early detection of primary vitreoretinal lymphoma ...

A study published in The New England Journal of Medicine has reported that the oral peptide icotrokinra, a selective ...

Using human iPSC-derived kidney organoids, researchers showed that NPHP1 deficiency triggers abnormal Hippo signaling that ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. This iPhone 16 rumor hub ...

Sun Pharma introduces Ilumya in India for treatment of moderate-to-severe plaque psoriasis: Our Bureau, Mumbai Tuesday, December 2, 2025, 14:45 Hrs [IST] Sun Pharma has announced ...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported another uplift in efficacy data from its Phase 1b trial of azer-cel, its allogeneic, off-the-shelf CD19 ...

What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

MoonLake Immunotherapeutics (MLTX) offers strong investment potential with key clinical trials and upcoming FDA milestones. See more analysis here.

New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...